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668Objectives: Cold agglutinins (CA) are circulating autoantibodies present in most humans. They are active below
normal body temperatures. Cold hemagglutinin disease involves the presence of CA sufficiently active at temper-
atures in the periphery to produce hemolysis or agglutination. Systemic hypothermia and cold cardioplegia may
result in agglutination or hemolysis. We reviewed the experience of a large referral center in managing patients
with CA and cold hemagglutinin disease undergoing cardiac surgery requiring cardiopulmonary bypass.
Methods: The electronic medical records from 2002 to 2010 were searched to identify patients with CA or cold
hemagglutinin diseasewho underwent cardiac surgery requiring cardiopulmonary bypass. Information related to
preoperative CA testing and treatment, surgery, cardiopulmonary bypass, postoperative complications, and mor-
tality was recorded.
Results: Sixteen patients underwent 19 procedures requiring cardiopulmonary bypass. Six patients had cold
hemagglutinin disease. The identification of CAwas made intraoperatively in 3 patients. One patient underwent
preoperative plasma exchange. Cold blood cardioplegia was used in 2 of 16 procedures using cardioplegia, with
the remaining using warmer blood cardioplegia. The lowest recorded intraoperative core temperature was less
than 34C in 1 case. CA-related postoperative hemolysis requiring transfusion was present in 1 patient, which
was resolved with active warming. No patient had evidence of permanent myocardial dysfunction, had a neuro-
logic event, required dialysis, or died within 30 days.
Conclusions: All patients with CA/cold hemagglutinin disease at the Mayo Clinic College of Medicine safely
underwent cardiac surgery without major adverse morbidity or mortality. Patients with CA but without evidence
of cold hemagglutinin disease can safely undergo normothermic cardiopulmonary bypass at 37C and warm car-
dioplegia without further testing. Patients with cold hemagglutinin disease should undergo laboratory testing
including CA titers and thermal amplitude and hematology consultation before cardiac surgery. (J Thorac Car-
diovasc Surg 2013;146:668-80)Cold agglutinins (CA) are autoantibodies that become ac-
tive at temperatures below physiologic body temperature.
These antibodies are present in most humans but are rarely
of clinical significance because they do not react at temper-
atures that are normally seen by the blood.1 Cold hemagglu-
tinin disease (CHAD) is characterized by the formation of
CA that are sufficiently active at temperatures achieved in
the peripheral circulation, such as the distal extremities on
exposure to cold, allowing hemolysis or agglutination to
occur.2,3
It is important to distinguish between CA and CHAD in
that one represents a benign variant of normal and the other
is a pathologic process. The benign and pathologic autoanti-
bodies are directed toward the same common red blood celle Departments of Anesthesiology,a Cardiovascular Surgery,b and Laboratory
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The Journal of Thoracic and Cardiovascular Surgantigens, most commonly IH, I, or i, but differ in that the be-
nign autoantibodies are usually polyclonal, cause agglutina-
tion or complement fixation at less than 25C, and have titers
less than 64 at 4C and less than 16 at 22C. The antibodies
in CHAD are usually monoclonal, cause agglutination or
complement fixation at 30C to 37C, and have titers greater
than 512 at 4C and greater than 128 at 22C.1
CHAD is responsible for 16% to 32% of all autoimmune
hemolytic anemias in both children and adults, with an esti-
mated prevalence of 10 to 16 cases per 1 million people.3-5
With rare exception, CHAD almost exclusively involves
immunoglobulin-M autoantibodies.3,6 The CA present in
CHAD bind to red blood cells at the colder temperature of
the peripheral body (eg, hands, feet, ears, and nose),
causing agglutination and complement fixation. Because of
the cooler temperatures, complement cannot activate but
remains on the red cell surface. On rewarming in the body’s
core, the CA release, but complement in the form of C3b
remains on red blood cells. Extravascular hemolysis occurs
predominantly in the liver as the complement-coated red
blood cells are removed by macrophages.2,7 The severity of
CHAD varies greatly among patients according to antibody
titer and thermal activity of the CA. Although CA do notery c September 2013
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CA ¼ cold agglutinins
CHAD ¼ cold hemagglutinin disease
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Barbara et al Perioperative Managementtypically react at temperatures greater than 30C, Rosse and
Adams8 report patients with CHAD antibodies active at nor-
mothermia (37C). CHAD may be a primary disorder or be
secondary to malignancy (most commonly lymphoma), in-
fection (infectious mononucleosis or Mycoplasma pneumo-
nia infection), or autoimmune diseases.2-4
Cardiac surgery requiring cardiopulmonary bypass
(CPB) and hypothermia carries a significant risk of morbid-
ity in patients with CA or CHAD. Systemic hypothermia
and cold cardioplegia may result in blood reaching temper-
atures that can cause agglutination and hemolysis.9,10
Hemolytic anemia11 and myocardial dysfunction12 have
been attributed to CA in patients undergoing hypothermic
CPB, whereas dysfunction of other end organs secondary
to CA is a hypothetical concern.3,9 Experience involving
patients with CA and CHAD undergoing cardiac surgery
requiring CPB consists of case reports and small series9,12
of less than 20 cases that do not distinguish patients with
CA from those with CHAD and case reports of patients
with CA and CHAD. The purpose of this study was to
review the recent experience of a single large tertiary
referral center in managing patients with CA or CHAD
undergoing cardiac surgery requiring CPB.P
MMATERIALS AND METHODS
This study was approved by the Mayo Foundation Institutional Review
Board. A computer-generated search of the electronic medical records
from 2002 to 2010 (the time period from the implementation of the elec-
tronic anesthesia record to the end of the searchable patient records at ini-
tiation of this study) was performed to identify patients aged 16 years or
greater with a diagnosis of CA, CHAD, or related diagnoses, such as
cold autoimmune hemolytic anemia, cold hemolysis, and paroxysmal
cold hemoglobinuria, who had given permission for their medical record
to be used for research. These patients were then cross-referenced for those
who underwent surgery requiring CPB. Individual patient records were
then reviewed by one of the authors (D.W.B.) to verify the presence of
CA or CHAD and surgery requiring CPB.
A standardized data-collection form was used. Demographic informa-
tion (age at time of surgery and gender) was recorded. The electronic med-
ical records of each patient were reviewed for preoperative information
related to the surgery (diagnosis and operation type) and CHAD or CA
(method of diagnosis; timing of diagnosis in relation to surgery; presence
of CHAD signs and symptoms, eg, anemia, hemolysis, acrocyanosis; cause
of CHAD, eg, infections, lymphoproliferative disorder, or unknown; pres-
ence of paroxysmal cold hemoglobinuria; CA antibody titer; CA thermal
amplitude; direct antiglobulin test; hemoglobin; creatinine; whether valvu-
lar pathology was thought to contribute to hemolysis as indicated in physi-
cian notes; dialysis dependency; ejection fraction from transthoracic
echocardiogram; lactate dehydrogenase; haptoglobin; and whether a hema-
tologist was consulted before surgery). Details of treatments of CHADThe Journal of Thoracic and Cawithin 90 days of surgery were recorded (plasma exchange; medical
therapies, including rituximab, cyclophosphamide, chlorambucil, and
glucocorticoids; intravenous immunoglobulin; history of splenectomy;
erythropoietin; and transfusions). Generalized anesthetic information con-
sisting of American Society of Anesthesiologists physical status classifica-
tion and emergency or scheduled nature of surgery was noted. The
intraoperative anesthetic record, surgical note, and perfusionist’s record
were reviewed for documentation of warming methods used; duration of
CPB; duration of aortic crossclamp; presence of circulatory arrest; cardio-
plegia techniques, including delivery method, temperature, composition,
intervals, number of doses, and specific notations by the surgeon or perfu-
sionist related to the cardioplegia; notations related to agglutination by
the surgeon or perfusionist; nadir nasal and bladder temperatures; use of
antifibrinolytics; and fluid and transfusion requirements. The postoperative
record was reviewed for details of vasoactive medication or intra-aortic bal-
loon pump (IABP) therapies as a marker of heart failure, transfusion
requirements, aforementioned laboratory studies (including hemoglobin na-
dir and creatinine peak in the first 2 postoperative days), chest tube output in
the first 48 postoperative hours, complications of transfusions as noted in the
daily progress notes, and death within 30 days. Statistical analysis consisted
of determination of mean standard deviation, median, and range for con-
tinuous variables and quantification (%) for categoric variables.RESULTS
We identified 16 patients with CA or CHAD who under-
went 19 cardiac procedures requiring CPB. Of these 16 pa-
tients, 6 had evidence of CHAD before surgery (Appendix
Table 1). Of the 10 patients with CA, 6 had CA identified
at the time of preoperative type and screen at the Mayo
Clinic College of Medicine or during CPB. The mean age
at the time of surgery was 69 15 years (median, 73 years;
range, 16-81 years), and 10 of 19 (53%) were male. Details
related to the CA or CHAD and preoperative testing are
shown in Appendix Table 1. No patient had a history of par-
oxysmal cold hemoglobinuria. None of the surgeries were
performed on an emergency basis. All procedures involved
patients with American Society of Anesthesiologists phys-
ical status classification 3 (74%) or 4 (26%).
Preoperative treatment of CHAD or treatments that could
have affectedCA levels or CHAD included plasma exchange
in 1 patient, glucocorticoids in 1 patient, and a history of sple-
nectomy in 1 patient. Patient 1 underwent preoperative
plasma exchange. A single 1.0 volume plasma exchange
was performed using the COBE Spectra version 7.0 software
(TerumoBCT, Lakewood, Colo) with ACD-A containing
7000 units of heparin as the anticoagulant. Replacement
was 5% normal serum albumin with 3 units of fresh-frozen
plasma at the end of the procedure. The choice of fresh-
frozen plasma as a replacement volumewas made to replace
coagulation factors before surgery. Patient 5 had received
prednisone 20 mg orally daily for 5 days preceding surgery
for bronchitis and not to treat the CA. Patient 14 had a history
of hemolytic anemiawith the presence of bothwarmand cold
autoantibodies. A splenectomy was performed months be-
fore cardiac surgery, with improvement in hemolysis after
this intervention. Patient 2 was transfusion dependent before
both surgeries because of ongoing hemolysis from CHADrdiovascular Surgery c Volume 146, Number 3 669
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and second procedures, respectively.
The surgeries performed, intraoperative CA manage-
ment, and fluid and transfusion requirements are detailed
in Appendix Table 2. Mean duration of anesthesia was
315  102 minutes (median, 302 minutes; range, 172-
541 minutes), CPB duration was 63  26 minutes (median,
61 minutes; range, 27-113 minutes), and aortic crossclamp
duration (when present) was 51  20 minutes (median,
51 minutes; range, 23-93 minutes). Three cases did not
use cardioplegia, 2 cases used cold blood cardioplegia at
10C, and 14 cases used blood cardioplegia at warmer tem-
peratures. Of note, no patient underwent circulatory arrest.
The lowest intraoperative nasal or bladder temperatures de-
creased to less than 35C in 3 cases and to less than 34C in
1 case. Of note, 3 patients (patients 5, 9, and 13) had the CA
identified in the operating room. For patients 5 and 9, the
perfusionist noted agglutination of blood in cardioplegia
heat exchanger with subsequent laboratory studies in both
cases confirming the presence of CA. Patient 13 had a rou-
tine type and screen drawn the morning of surgery and was
then anesthetized for cardiac surgery. Before skin incision,
the blood bank reported that a strong reacting antibody was
present and that the antibody screen was unable to be com-
pleted that day. Surgery was postponed, and the hematology
team was consulted. A cold autoantibody was identified,
and additional laboratory studies demonstrated no evidence
of hemolysis. Surgery was performed using warm blood
cardioplegia and avoidance of hypothermia.
Postoperative events, including vasoactive medications
and IABP requirements, transfusions, hospital length of
stay, and 30-day mortality, are shown in Appendix Table 3.
Two patients required an IABP. Ten patients required inotro-
pic support with epinephrine, dopamine, or milrinone. No
patient required dialysis postoperatively. There were no re-
ported transfusion-related complications noted in the postop-
erative period.Nopatient had a neurologic event. In nopatient
was additional therapy (other than transfusion) required for
treatment of CA or CHAD. After the initial aortic valve re-
placement, patient 2 experienced hemolysis on postoperative
days 3 to 5, during which time the hematology consultation
service was actively involved, the patient was transfused,
and active warming of the patient was used. Polyspecific
direct antiglobulin tests were performed on postoperative
days 2, 4, and 5, and they were weakly positive, 2þ, and
1þ, respectively. Antibody testing was again performed, re-
vealing only cold autoantibodies. Plasma exchange was con-
sidered, but the hemolysis resolvedwithout further treatment.
DISCUSSION
The key finding in this study is that patients from the
Mayo Clinic College of Medicine with benign CA or CA
causing CHAD underwent cardiac surgery safely with
CPB and experienced relatively unremarkable670 The Journal of Thoracic and Cardiovascular Surgpostoperative courses, with the exception of 1 case of post-
operative hemolysis. When cardioplegia was used, solely
anterograde or anterograde in conjunction with retrograde
blood cardioplegia was used. For patients with known CA
or CHAD preoperatively, cold (10C) blood cardioplegia
was used intentionally in only 1 case of benign CA with
low antibody titers. In addition, in the 4 procedures in which
patients received doses of cardioplegia that were 30C or
less, there were no adverse outcomes. In all cases of known
CA or CHAD, efforts were made to maintain normothermia
of 37C intraoperatively.
Laboratory testing relevant to CHAD includes those re-
lated to hemolysis (hemoglobin, direct antiglobulin test, lac-
tate dehydrogenase, haptoglobin, free plasma hemoglobin,
and bilirubin) and others related to the quantification and ac-
tivity of CA antibodies (CA antibody titer and thermal
amplitude, respectively).3,9,11 The method of CA titer
quantification at the Mayo Clinic College of Medicine is
detailed in Appendix 4. There is potential for inaccuracy
and significant interoperator variability in performing anti-
body titers because of the subjective nature of the end point
of the reaction.8 There is no consensus on the CA antibody
titer that is clinically significant and warrants appropriate
precautions. Although titers greater than 64 are considered
elevated, CHAD and hemolysis at the temperature reached
in the peripheral circulation rarely occur unless titers are
greater than 1000.13 Previous reports of patients with CA un-
dergoing CPB have cited a titer range from greater than 32 to
greater than 1000 as clinically significant.12,14,15 Thermal
amplitude correlates antibody activity to temperature and is
commonly reported by measuring the highest temperature
at which agglutination is observed in vitro. Increasing
thermal amplitude signifies autoantibody activity at
warmer temperatures and thus more readily facilitates
complement fixation potentially resulting in red blood cells
hemolysis.3,8,9 Thermal amplitude determination may be
beneficial to determine whether systemic hypothermia or
cold cardioplegia administration will be tolerated if there is
a strong surgical indication for either. As previously
indicated, all patients will have naturally occurring cold
agglutination when the temperature is decreased to levels
that are rarely clinically relevant (eg, 4C).1 Clinical severity
of CHAD is more closely related to thermal amplitude than
antibody titer.16 Somehave recommended that all patients re-
quiringCPBundergo rigorous testing for CA, including ther-
mal amplitude, antibody titer, and antigen specificity
determination,17,18 but others have questioned the utility
and feasibility of this recommendation.19,20 In Figure 1, we
suggest an algorithm to guide preoperative testing in patients
with CA and CHAD.
Routine blood antibody screening in the Mayo Clinic
College of Medicine’s blood bank is performed initially at
24C and then after incubating at 37C. Detection of agglu-
tination during immediate spin antibody screening orery c September 2013
Cardiac surgery requiring CPB in a patient with CA or CHAD 
Benign CA
(Asymptomatic patient without 
history or evidence of cold-
induced hemolysis or 
agglutination) 
Avoid systemic 
hypothermia and cold 
cardioplegia without 
additional testing related 
to CA. 
or
If systemic hypothermia 
or cold cardioplegia are 
required, CA titer ± 
thermal amplitude with 
consideration of 
hematology consultation 
given planned surgery and 
laboratory results. 
CHAD  
(History or evidence of hemolysis 
or agglutination) 
CA titers, thermal 
amplitude, and 
hematology consultation 
for consideration of 
preoperative treatment to 
decrease CA titers. 
FIGURE 1. Recommendations for preoperative testing and hematology
consultation in patients with benign CA and CHAD. CPB, Cardiopulmo-
nary bypass; CA, cold agglutinins; CHAD, cold hemagglutinin disease.
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Mduring ABO typing, which occurs at room temperature,
may represent CA. This was how CAwere initially identi-
fied in 4 patients (25%) in the current study. In these
patients, there was no preexisting diagnosis of CA or
CHAD, and none had preoperative symptoms of CHAD.
Although only 1 of these patients (patient 13) underwent
further CA testing that consisted of CA titer determination,
further laboratory testing such as thermal amplitude and CA
titers may aid the clinician in management, especially in pa-
tients in whom deep hypothermia is considered.
Preoperatively, 6 patients (38%) in this study had clinical
manifestations of CHAD. Medical therapies for patients
with CHAD or CA include plasma exchange, rituximab, cy-
clophosphamide, chlorambucil, glucocorticoids, intravenous
immunoglobulin, splenectomy (although rarely effective for
CHAD), erythropoietin, and red blood cell transfusions (the
latter 2 therapies serve to treat anemia and not CA produc-
tion).2,4,7,9,10,16,21-23 In our series, only 1 patient underwent
plasma exchange, 1 patient required preoperative red blood
cell transfusion before both surgeries, and 1 patient had
undergone splenectomy because of the concomitant
presence of warm autoantibodies. Plasma exchange provides
a rapid, reliable, and temporary reduction in CA antibody
titer and is often used for patients with CHAD but, alongThe Journal of Thoracic and Cawith the other treatments mentioned earlier, may not
be appropriate or indicated for patients who simply had
CA without the presence of hemolysis.2,23 Preoperative
consultation with physicians from our Department of
Hematology was obtained in the majority of patients. The
hematologists serve as part of the multidisciplinary team
approach to patient care in guiding and interpreting
necessary preoperative testing, assisting with preoperative
reduction of CA if necessary, and consulting with the
surgeon to delineate risks and benefits of CPB temperature
management in relation to an individual’s planned operation
and CA severity. Although not all hematologists may have
an interest in benign hematology including CA, this area
should be covered in hematologists’ training and they should
have the ability to assist in perioperative laboratory testing
and management of patients with CA or CHAD. Otherwise,
referral should be made to a hematologist or tertiary care
center equipped to assist in the perioperative management.
Of particular challenge is the patient with CA that is dis-
covered intraoperatively. In the present study, the presence
of CAwas diagnosed intraoperatively in 3 patients (19%).
Because these patients did not demonstrate signs or symp-
toms of CHAD, these antibodies seemed to be the benign
cold autoantibodies that represent a variant of normal. In
1 patient, CPB had been instituted, cold anterograde cardi-
oplegia was administered, and agglutination was noted in
the cardioplegia heat exchanger. Warm blood cardioplegia
was immediately administered, and the patient was kept
normothermic on CPB. A second patient was noted to
have agglutination in the CPB circuit before institution of
CPB. Anterograde warm blood cardioplegia and normo-
thermic CPBwere used. In a third patient, surgery was post-
poned to allow further workup when the preoperative type
and screen revealed a strongly active antibody.
Previous reports have described management of patients
in whom the diagnosis of CA disease was made intraopera-
tively, as shown in Table 1.12,17-19 These strategies serve to
mitigate further agglutination in the coronary circulation
and the potential for myocardial damage by avoiding
further cardioplegia, returning the patient to normother-
mia, attempting to wash microemboli from the coronary
circulation, or changing from blood to crystalloid
cardioplegia. However, crystalloid cardioplegia may provide
inferior myocardial protection when compared with blood
cardioplegia.24
Intraoperative management of patients with CA and
CHAD can be divided into 2 major areas: measures unre-
lated to CPB to avoid sequelae of CA disease and manage-
ment strategies pertaining to CPB and cardioplegia. Our
practice has been strict avoidance of hypothermia whenever
feasible with use of forced-air warming devices and warmed
intravenous fluids, as other authors have recommended.20,21
The lowest intraoperative temperatures recorded in our
series were higher than those reported in a previous seriesrdiovascular Surgery c Volume 146, Number 3 671
TABLE 1. Cardiopulmonary bypass and cardioplegia management strategies for cold agglutinins
Management strategies for patients with CA diagnosed preoperatively
Avoidance of cardioplegia (current series)15
Warm blood cardioplegia and systemic normothermia (current series)9,26
Complete coronary and cardiac washout with intermittent cold crystalloid cardioplegia in conjunction with systemic hypothermia9,15,18,27
Continuous anterograde or retrograde warm blood cardioplegia25,28
Warm crystalloid cardioplegia followed by cold crystalloid cardioplegia12,27
Intermittent anterograde or continuous retrograde warm blood cardioplegia and moderate hypothermia9
Use cold (4C) blood cardioplegia in patients with CA and low thermal amplitudes12
Management strategies for patients with CA discovered intraoperatively
Warm blood cardioplegia on notation of agglutination after administration of cold blood cardioplegia (current series)
Retrograde cold crystalloid cardioplegia to facilitate removal of coronary microemboli caused by anterograde cold blood cardioplegia17
Anterograde cold crystalloid cardioplegia on notation of agglutination in the cardioplegia heat exchanger after administration of anterograde cold blood
cardioplegia12
Discontinuation of cardioplegia and hypothermia after notation of agglutination in the coronary circulation on administration of cold cardioplegia18
Avoidance of cardioplegia after notation of agglutination in the cardioplegia heat exchanger before institution of CPB19
Use of crystalloid cardioplegia and only moderate systemic hypothermia (32C) on CPB with careful monitoring by the perfusionist for presence of
agglutination12
CPB, Cardiopulmonary bypass; CA, cold agglutinins.
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described multiple different techniques to successfully
manage patients with CA intraoperatively, as shown in
Table 1.9,12,15,18,25-28 One study specifically noted no
difference in hemolysis during CPB between patients with
and without CA.29 Other authors have reported that cold
blood cardioplegia can be safely used in patients with CA
even if visible intracoronary agglutination is noted, but
this stance is controversial.30 Successful off-pump coronary
artery bypass has been reported in a patient with CHAD.31 In
our practice, we avoid systemic hypothermia by using nor-
mothermic CPB at 37C with no cardioplegia when cardiac
arrest can be avoided or intermittent anterograde warm
blood cardioplegia at 37C (occasionally in conjunction
with continuous retrograde warm blood cardioplegia). The
small sample size of our series and the limited number of
other small series and case reports make it difficult to
draw definitive conclusions regarding the most suitable
CPB and cardioplegia technique. As with the majority of
patients in our series lacking CA laboratory testing to define
thermal spectrum of activity, using CPB and cardioplegia
techniques that avoid risk of agglutination and hemolysis
in the coronary and systemic circulations seems to be
a safe and generally acceptable practice. In asymptomatic
patients with low CA antibody titers, it has been suggested
that hypothermic CPB may be safely performed, as was
observed with patient 16 in our series.14
Although no patients in our series required deep hypo-
thermic circulatory arrest, case reports of patients with
CA32 and CHAD22 successfully undergoing deep hypother-
mia above the thermal amplitude exist. In these cases, the
thermal amplitude was used to guide a safe level of
hypothermia.
No patient in the present series died within 30 days of sur-
gery. Case reports of death within 30 days of cardiac surgery672 The Journal of Thoracic and Cardiovascular SurgrequiringCPB exist, but the causewas not directly attributed
to CA.12 All but 5 procedures in our series required postop-
erative red blood cell transfusions. In only 1 patient (patient
2) was treatment considered for CHAD due to ongoing post-
operative hemolysis. In this case, plasma exchangewas con-
sidered; however, the hemolysis resolved after conservative
management consisting of actively warming the patient.
Prolonged postoperative hemolysis has been reported in
a patient with CA undergoing cardiac surgery with hypo-
thermia.11 This is a rare complication that we did not note
in our practice and has not been shown in other series.9,12,14
In the 11 patients requiring postoperative vasoactive
medications, the requirements were consistent with
preoperative myocardial function and type of operation. In
none of these patients was the vasoactive requirement
unexpected such that we would have been concerned
about CA-induced myocardial ischemia.
Study Limitations
This study has all the inherent limitations of a retrospec-
tive case series, including uncertainty of reasons for man-
agement decisions and charting omissions. By definition,
only patients undergoing cardiac surgery requiring CPB
were included. Therefore, patients undergoing off-pump
cardiac surgery were not included. Cases of patients with
CA undergoing CPBmay have been missed if they were un-
diagnosed perioperatively or excluded because they were
aged less than 16 years, because CA occur in childhood
as well. Patients’ blood was likely exposed to temperatures
lower than the minimummeasured temperatures reported in
Appendix Table 2 because of the CPB circuit temperature
being less than the patients’ nadir temperatures. In addition,
it is important to note that blood cardioplegia is diluted with
crystalloid, resulting in reduced CA levels in the cardiople-
gia that may decrease the incidence of intraoperativeery c September 2013
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increasing trend of normothermic CPB in recent years
may have reduced the number of CA discovered intraoper-
atively and the perioperative complications related to CA.
Finally, no patients with CA or CHAD underwent deep hy-
pothermic circulatory arrest in this study.
CONCLUSIONS
CHAD is a rare condition, and benign CA, although a var-
iant of normal, rarely are detectable on routine screening and
therefore is also uncommon in patients undergoing CPB. As
outlined in Figure 1, patients with benign CA (but without
evidence of CHAD) who can safely undergo cardiac surgery
with normothermia andwarmcardioplegia at 37Cdo not re-
quire additional testing. If systemic hypothermia or cold car-
dioplegia is required, the following are recommended for
patients with benign CA: CA titers, thermal amplitude,
and hematology consultation to assist with perioperative
CA management, if necessary, given laboratory results and
planned surgery. Although not recommended for all patients
with benign CA, the most conservative preoperative labora-
tory testing on a case-by-case basis would include CA titers
and thermal amplitudes, in the unlikely event of an unantic-
ipated intraoperative emergency requiring hypothermia or
circulatory arrest. Patients with CHAD require preoperative
laboratory testing and hematology consultation for consider-
ation of appropriate preoperative CA management. Finally,
we are unable to make recommendations regarding theman-
agement of pediatric patients with benign CA or CHAD un-
dergoing cardiac surgery, because this patient population
was excluded from the current study.
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APPENDIX TABLE 1. Preoperative characteristics and findings of patients with cold agglutinins undergoing surgery requiring cardiopulmonary
bypass
Patient
no.
Age at
surgery (y)/gender
CA or
CHAD How diagnosed Time of diagnosis Cause
Symptoms
of CHD
documented
CA titer
at 4C* Thermal amplitude (C)
1 16 F CHAD Anemia workup Preoperatively Unknown Yes 256 NP
2 74 F CHAD Preexisting diagnosisz Preoperatively Lymphoproliferative
disorder
Yes 8192 3þ at 30C, 4þ at 26C
2 77 F CHAD Preexisting diagnosis Preoperatively Lymphoproliferative
disorder
Yes >512 3þ at 30C, 4þ at 26C
3 68 F CA Preexisting diagnosis Preoperatively Postinfectious No 128 wþ to 1þ at 30C, 2þ to 3þ at
22C, no reaction at 37C
4 76 M CHAD Preexisting diagnosis Preoperatively Unknown Yes 131,072 NP
5 73 M CA Agglutination on CPB Intraoperatively Postinfectious No NP NP
6 81 F CHAD Preexisting diagnosis Preoperatively Unknown Yes 64-512 NP
7 80 M CHAD Preexisting diagnosis Preoperatively Unknown Yes >512 Negative at 37, negative at 30,
and wþ at 22 per outside
hospital
8 69 F CHAD Preexisting diagnosis Preoperatively Unknown Yes 160x NP
9 42 M CA Agglutination in CPB
circuit before
institution of CPB
Intraoperatively Unknown No NP NP
10 66 M CA Blood type and screen
day of surgery
Preoperatively Lymphoproliferative
disorder
No NP NP
11 74 F CA Preexisting diagnosis Preoperatively Unknown No <64 22C per outside hospital
12 67 M CA Preoperative blood type
and screen
Preoperatively Unknown No NP NP
13 76 M CA Preoperative blood type
and screen
Intraoperativelyk Unknown No >512 NP
13 76 M CA Preoperative blood type
and screen
Intraoperativelyk Unknown No >512 NP
14 80 M CA Anemia workup Preoperatively Unknown Yes{ 8 NP
15 71 M CA Preoperative blood type
and screen
Preoperatively Unknown No NP NP
16 68 F CA Anemia workup Preoperatively Unknown No 2 NP
16 69 F CA Anemia workup Preoperatively Unknown No 2 NP
All laboratory testing was performed at Mayo Clinic unless indicated otherwise. CA, Cold agglutinins; CHAD, cold hemagglutinin disease; CPB, cardiopulmonary bypass;
CHD, congestive heart disease;DAT, direct antiglobulin test; NP, not performed; EF, ejection fraction;Hb, hemoglobin; Cr, creatinine; LDH, lactate dehydrogenase; anti-G, anti–
immunoglobulin-G direct antiglobulin test; anti-C, anti-complement direct antiglobulin test;mþ, microscopic positive only; poly, polyspecific direct antiglobulin test; wþ, weak
positive. *The manner in which titers are quantified at Mayo Clinic was changed during this retrospective study. Before the change, titers were reported as exact titer values, and
subsequently they are reported as ranges with an upper level of>512. yA polyspecific direct antiglobulin test detects the presence of immunoglobulin-G or complement. Specific
direct antiglobulin test consists of anti–immunoglobulin-G and anti-complement testing. Test results are graded on a scale of increasing positivity as negative, microscopic
positive, weak positive, 1þ, 2þ, 3þ, and 4þ. zPreexisting diagnosis signifies patient presented to Mayo Clinic with the diagnosis of CA or CHAD from the referring institution.
xThis CA titer was reported from an outside institution. kTwo days before the patient underwent CPB, a routine type and antibody screen were drawn. He was then anesthetized,
and venous and arterial access was secured. The blood bank notified the operating room staff that because of a strong reacting antibody, the antibody screen was unable to be
completed that day. Surgery was postponed, and the patient was awakened and taken to the cardiac surgical unit to await the results of the antibody screen and have a hematology
consult. A cold autoantibody was identified, and additional laboratory studies demonstrated no evidence of hemolysis. Hematology recommended proceeding with surgery and
using only warm cardioplegia while avoiding hypothermia. {Despite the presence of autoimmune hemolytic anemia in this patient with both CA and warm autoantibodies, the
laboratory results were consistent with warm autoantibodies causing hemolysis and not CHAD.
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DATy
Valvular pathology
contributing to hemolysis
EF
(%)
Hb
(g/dL)
Cr
(mg/dL)
Bilirubin total/
direct (mg/dL)
LDH (U/L)
(normal, 122-222)
Haptoglobin (mg/dL)
(normal, 30-200)
Hematology
consult before
surgery
Poly negative No 64 10.4 0.9 1.2/0.3 234 (pediatric reference range,
105-233)
31 Yes
Poly 2þ
Anti-G mþ
Anti-C 2þ
No 64 6.8 0.7 4.1/0.3 381 NP Yes
Poly 1þ
Anti-G negative
Anti-C 1þ
Yes 37.5 9.4 0.6 6.1/1.2 904 <14 Yes
Poly 1þ
Anti-G negative
Anti-C 1þ
No 52.5 11.3 1.9 0.6/0.2 217 NP Yes
Poly 1þ
Anti-G wþ
Anti-C wþ
No 70 12.1 0.9 NP 252 NP Yes
NP No 60 13.1 0.9 NP NP NP No
Poly wþ
Anti-G NP
Anti-C NP
No 70 11.9 1 Total 1 517 157 Yes
Poly 1þ
Anti-G negative
Anti-C wþ
No 23 13 1.4 1.7/0.6 268 NP Yes
NP No 66 15 0.8 0.9/0.3 NP NP Yes
Poly wþ
Anti-G negative
Anti-C wþ
No 63 14.8 0.9 1/0.3 NP NP No
NP No 58 14 1 0.7/0.2 176 NP No
NP No 60 11.9 1 NP NP NP Yes
NP No 43 13.2 1.2 0.6/0.2 NP NP No
NP No 68 11.8 0.8 Direct 0.2 130 94 Yes
NP No 68 11.8 0.8 Direct 0.2 130 94 Yes
Poly 1þ
Anti-G 1þ
Anti-C negative
No 62 10.5 1.4 0.5/.1 210 72 Yes
Poly wþ
Anti-G negative
Anti-C wþ
No 73 13.6 1.1 NP NP NP No
Poly negative
Anti-G NP
Anti-C NP
Yes 49 10.9 1.3 2.6/0.6 NP <14 Yes
Poly negative
Anti-G NP
Anti-C NP
Yes 42.5 10.2 0.9 NP NP <14 Yes
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APPENDIX TABLE 2. Intraoperative findings and management of patients with cold agglutinins undergoing surgery requiring cardiopulmonary
bypass
Patient
no. Procedure(s)
Anesthesia
duration (min) Warming methods used CP route
CP temperature
and composition
Continuous
retrograde
CP
CP
intervals
(min)
1 Tricuspid valve re-replacement
(mechanical)
364 Not specified None NA No NA
2 Aortic valve replacement
(bioprosthetic)
172 Two FAW, IVFW, OR kept
warm
Anterograde Warm* blood No 15
2 Aortic valve re-replacement
(mechanical)
236 FAW, IVFW, OR kept at 80F,
blood samples kept warm on
transport to laboratory
Anterograde Warm blood No 20
3 Aortic valve replacement
(bioprosthetic), foramen
ovale closure
303 FAW, IVFW Anterograde
and retrograde
Warm blood Yes 15-20
4 Aortic valve replacement
(bioprosthetic)
198 FAW, IVFW for all venous
lines, OR kept at 75F
Anterograde Warm blood No NA
5 Aortic valve replacement
(bioprosthetic)
217 FAW, IVFW Anterograde Cold (10C) blood
followed by warm
blood on discovery
of agglutinationy
No 20
6 Aortic valve replacement
(bioprosthetic), CABG
355 FAW, IVFW Anterograde Warm bloodz No 5-10
7 Aortic valve replacement
(bioprosthetic), CABG 31
359 FAW, multiple IVFW, OR kept
at 78F
Anterograde Warm blood No 10
8 Tricuspid valve repair 221 FAW, IVFW None NA No NA
9 Mitral valve repair 222 FAW, IVFW Anterograde Warm blood No 15-20
10 CABG 541 FAW, IVFW for all venous lines Anterograde
and retrograde
Warm blood No 20
11 Mitral valve re-replacement
(mechanical), tricuspid valve
repair
476 FAW, IVFW Anterograde
and retrograde
28C blood Yes 20-25
12 CABG 301 FAW, IVFW Anterograde and
via vein graft
30C-34C bloodz No 15-20
13x Aortic valve replacement
(bioprosthetic)
424 FAW, IVFW, OR kept warm Anterograde Warm blood No 15
13x Ascending aorta repair See above row FAW, IVFW, OR kept warm None NA No NA
14 Aortic valve replacement
(bioprosthetic)
345 FAW, IVFW Anterograde Warm blood No 20
15 Aortic valve replacement
(bioprosthesis, CABG)
271 FAW, IVFW Anterograde Warm blood No 20
16k CABG, mechanical mitral
perivalvular leak repair
411 FAW, IVFW Anterograde Warm blood No 20
16 Mechanical mitral perivalvular
leak re-repair, tricuspid valve
annuloplasty
260 FAW, IVFW Anterograde Cold blood (10C) No 20
CP, Cardioplegia; CPB, cardiopulmonary bypass; RBC, red blood cell; FFP, fresh-frozen plasma; CABG, coronary artery bypass grafting; FAW, forced-air warmer; IVFW,
intravenous fluid warmer; OR, operating room; NA, not applicable; TA, tranexamic acid; ACA, aminocaproic acid. *Warm blood cardioplegia indicates a temperature of 35C to
37C. yPerfusionist noted agglutination of blood in cardioplegia heat exchanger. Cold cardioplegia was then discontinued and warm cardioplegia administered. zDifficulty in
arresting the heart was noted by the surgeon in these 2 patients. xThis patient required a second CPB run after completion of the aortic valve replacement because of electro-
mechanical dissociation during sternal closure. Cardiac massage was initiated, and intravenous epinephrine was administered. Because of tearing of the aortic suture line, the
patient was re-heparinized and CPB reinitiated to facilitate repair of the ascending aorta. Thirty minutes after weaning from the second CPB run, an IABP was placed. Several
hours were then spent normalizing coagulation and surgically achieving hemostasis. The duration of anesthesia (424 minutes) included both CPB runs. kBleeding in the
atrioventricular groovewas encountered and surgically repaired after aortic crossclamp removal and before discontinuation of CPB. An IABPwas placed to reduce left ventricular
pressures to preserve the repair.
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Total CP
doses
Circulatory
arrest
CPB/
crossclamp
duration (min)
Lowest
nasal/bladder
temperature (C)
Agglutination
noted in
operating room
Antifibrinolytic
used
RBC
transfusion
(units)
FFP
transfusion
(units)
Platelet
transfusion
(units)
Cryoprecipitate
transfusion
(units)
NA No 58/0 35.5/35.6 No Aprotinin 3 1 0 0
2 No 35/30 36.2/36.2 No None 4 0 0 0
2 No 45/28 36.4/36.9 No TA 3 0 0 0
6 No 112/77 35.8/36.1 No TA 0 0 0 0
1 No 29/23 36.2/36.3 No None 1 0 0 0
2 No 68/58 33.4/34.5 Yesy TA 0 0 0 0
6 No 81/68 36/36.6 No None 2 0 0 0
4 No 45/35 35.9/36.9 No ACA 0 0 0 0
NA No 35/0 35.3/35.7 No ACA 1 2 1 0
3 No 58/48 35.9/36.1 Yes None 0 0 0 0
4 No 79/62 35.6/35.9 No None 4 6 1 0
3 No 113/93 35/35.5 No None 3 3 2 0
5 No 86/66 35.7/36.1 No None 0 2 0 0
2 No 39/30 36.5/36.8 No None 11 8 4 2
NA No 27/0 36.5/36.8 No None See above
row
See above
row
See above
row
See above
row
Not present
in records
No 61/53 34.6/35 No TA 2 0 0 0
3 No 76/63 35.9/36.1 No TA 0 0 0 0
2 No 75/35 34.5/35.1 No None 4 2 1 0
2 No 71/40 35/35.5 No Aprotinin 3 2 0 0
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APPENDIX TABLE 3. Postoperative findings in patients with cold agglutinins undergoing surgery requiring cardiopulmonary bypass
Patient no. Preoperative EF (%)
IABP or vasopressor with highest dose
(initiation time/length of use) RBC transfusion Platelet (units) FFP (units)
Cryoprecipitate
(units)
1 64 Epinephrine 0.07 mg/kg/min (OR/2 d)
Milrinone 0.5 mg/kg/min (OR/1 d)
1.5 units on POD 6 0 0 0
2 64 None 2 units on POD 3,
1 unit on POD 5
0 0 0
2 37.5 None 2 units on POD 1,
1 unit on POD 5
0 0 0
3 52.5 Dopamine 2 mg/kg/min (OR/2 d)
Epinephrine 0.02 mg/kg/min (POD 2/4 h)
1 unit on POD 2,
2 units on POD 3
0 0 0
4 70 None 2 units on POD 3 0 0 0
5 60 None 1 unit on POD 1 0 0 0
6 70 Milrinone 0.5 mg/kg/min (OR/3 d)
Vasopressin 0.02 U/min (OR/3 h)
0 0 0 0
7 23 Epinephrine 0.08 mg/kg/min (OR/1 d) 1 unit on POD 2 0 0 0
8 66 Vasopressin 0.04 U/min (POD 0y/12 h)
Dopamine 3 mg/kg/min (POD 0/12 h)
0 0 0 0
9 63 None 0 0 2 0
10 58 None 1 unit on POD 1 0 0 0
11 60 Epinephrine 0.03 mg/kg/min (OR/12 h)
Milrinone 0.5 mg/kg/min (OR/6 h)
0 0 0 0
12 43 None 3 units on POD 1,
2 units on POD 3
0 0 0
13 68 Epinephrine 0.05 mg/kg/min (OR/2 d)
Vasopressin 0.04 U/min (OR/2 d)
IABP (OR/1 d).
1 unit on POD 3 0 0 2
13 68 See above row See above row See above row See above row See above row
14 62 None 2 units on POD 4 0 0 0
15 73 Epinephrine 0.02 mg/kg/min (OR/1 d) 2 units on POD 4 0 0 0
16 49 Dopamine 2 mg/kg/min (OR/4 d)
IABP (OR/3 d)
1 unit on POD 5 0 0 0
16 42.5 Epinephrine 0.05 mg/kg/min (OR/1 d) 0 0 0 0
A polyspecific direct antiglobulin test detects the presence of immunoglobulin-G or complement. Specific direct antiglobulin test consists of anti–immunoglobulin-G and anti-
complement testing. Test results are graded on a scale of increasing positivity as negative, microscopic positive, weak positive, 1þ, 2þ, 3þ, and 4þ. EF, Ejection fraction; IABP,
intra-aortic balloon pump; RBC, red blood cell; POD, postoperative day; poly, polyspecific direct antiglobulin test; FFP, fresh-frozen plasma; LDH, lactate dehydrogenase;
Hb, hemoglobin; RR, reference range; CT, chest tube; CA, cold agglutinins; T/D, total/direct; wþ, weak positive; OR, operating room; MI, myocardial infarction.
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Hemolysis laboratory studies
(bilirubin mg/dL, haptoglobin mg/dL,
hemoglobin g/dL, LDH U/L)
Hb nadir in
first 2 d
postoperatively
(g/dL)
CT output in
first 2 d
postoperatively (L)
Creatinine peak in
first 2 d postoperatively
(mg/dL)
Postoperative
MI
Hospital
length
of stay (d)
Death within
30 d
POD 6: haptoglobin<14, LDH 351,
poly negative, CA titer 128,
bilirubin T/D 1.2/0.3
9.9 1 1.1 No 18 No
POD 2: poly wþ
POD 3: LDH 551, bilirubin T/D 7.3/2.2
POD 4: poly 2þ, LDH 585, bilirubin
8.7/4
POD 5: poly 1þ, LDH 568, bilirubin
T/D 6.5/2.4
POD 6: bilirubin 6.1/1.5
8.6 0.46 0.8 No 6 No
POD 5: poly 1þ, plasma Hb 42.4
(RR 0-15), haptoglobin<14,
bilirubin T/D 4.3/1.4, LDH 458
8.8 2.4 0.5 No 6 No
POD 3: poly weak þ
No other hemolysis laboratory tests
drawn
8.3 0.31 1.5 No 6 No
POD 4: Haptoglobin 29, LDH 366,
bilirubin 2.4/0.5, CA screen
positive, CA titers 65,536
8.4 0.79 0.8 No 6 No
POD 2: CA screen positive, titers>512
No other hemolysis testing done
8.6 0.89 0.9 No 5 No
No hemolysis testing done 10.4 0.9 1.1 No 7 No
No hemolysis testing done 8.8 0.88 2 No 5 No
No hemolysis testing done 9.9 1.27 0.7 No 5 No
No other hemolysis testing done 10 1.21 1 No 5 No
No hemolysis testing done 9.1 1.3 1.2 No 4 No
No hemolysis testing done 9.2 2.8 0.9 No 7 No
No hemolysis testing done 8 1.5 1.2 No 5 No
POD 4: bilirubin T/D 1.3/0.4, LDH 495.
POD 6: bilirubin T/D 1/0.4 LDH 428.
9.4 1.65 1.7 No 10 No
See above row See above row See above row See above row No See above
row
No
POD 4: poly 1þ
No other hemolysis testing done
8.9 0.54 1.7 No 5 No
POD 4: poly wþ 9 0.94 1 No 5 No
No hemolysis testing done 10.4 1.1 1.3 No 10 No
No hemolysis testing done 11.3 0.8 1 No 11 No
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APPENDIX 4. METHOD OF COLD AGGLUTININS
ANTIBODY TITER DETERMINATION
The CA antibody titer is performed on serum or plasma.
The samples are collected and maintained at 37C. For se-
rum samples, the blood is allowed to clot at 37C, whereas
for plasma samples, the plasma is separated from the whole
blood at 37C. Serial dilutions are made of the sample using
phosphate-buffered saline. This is tested against 2 drops of
3% to 5% suspension of pooled group O red blood cells.
The cells are incubated in the dilutions at 4C for 1 to
2 hours. They are then centrifuged and stored in a rack in
an ice water bath until read.13
Perioperative Management Barbara et al
P
M680 The Journal of Thoracic and Cardiovascular Surgery c September 2013
